Show simple item record

FieldValueLanguage
dc.contributor.authorFeng, Zhichaoen_AU
dc.contributor.authorShen, Huien_AU
dc.contributor.authorGao, Kaien_AU
dc.contributor.authorSu, Jianpoen_AU
dc.contributor.authorYao, Shanhuen_AU
dc.contributor.authorLiu, Qinen_AU
dc.contributor.authorYan, Zhiminen_AU
dc.contributor.authorDuan, Junhongen_AU
dc.contributor.authorYi, Dalien_AU
dc.contributor.authorZhao, Huafeien_AU
dc.contributor.authorLi, Huilingen_AU
dc.contributor.authorYu, Qizhien_AU
dc.contributor.authorZhou, Wenmingen_AU
dc.contributor.authorMao, Xiaowenen_AU
dc.contributor.authorOuyang, Xinen_AU
dc.contributor.authorMei, Jien_AU
dc.contributor.authorZeng, Qiuhuaen_AU
dc.contributor.authorWilliams, Lindyen_AU
dc.contributor.authorMa, Xiaoqianen_AU
dc.contributor.authorRong, Pengfeien_AU
dc.contributor.authorHu, Dewenen_AU
dc.contributor.authorWang, Weien_AU
dc.date.accessioned2021-06-02T04:54:48Z
dc.date.available2021-06-02T04:54:48Z
dc.date.issued2021
dc.identifier.urihttps://hdl.handle.net/2123/25159
dc.description.abstractObjectivesTo develop and validate a machine learning model for the prediction of adverse outcomes in hospitalized patients with COVID-19.MethodsWe included 424 patients with non-severe COVID-19 on admission from January 17, 2020, to February 17, 2020, in the primary cohort of this retrospective multicenter study. The extent of lung involvement was quantified on chest CT images by a deep learning–based framework. The composite endpoint was the occurrence of severe or critical COVID-19 or death during hospitalization. The optimal machine learning classifier and feature subset were selected for model construction. The performance was further tested in an external validation cohort consisting of 98 patients.ResultsThere was no significant difference in the prevalence of adverse outcomes (8.7% vs. 8.2%, p = 0.858) between the primary and validation cohorts. The machine learning method extreme gradient boosting (XGBoost) and optimal feature subset including lactic dehydrogenase (LDH), presence of comorbidity, CT lesion ratio (lesion%), and hypersensitive cardiac troponin I (hs-cTnI) were selected for model construction. The XGBoost classifier based on the optimal feature subset performed well for the prediction of developing adverse outcomes in the primary and validation cohorts, with AUCs of 0.959 (95% confidence interval [CI]: 0.936–0.976) and 0.953 (95% CI: 0.891–0.986), respectively. Furthermore, the XGBoost classifier also showed clinical usefulness.ConclusionsWe presented a machine learning model that could be effectively used as a predictor of adverse outcomes in hospitalized patients with COVID-19, opening up the possibility for patient stratification and treatment allocation.Key Points• Developing an individually prognostic model for COVID-19 has the potential to allow efficient allocation of medical resources.• We proposed a deep learning–based framework for accurate lung involvement quantification on chest CT images.• Machine learning based on clinical and CT variables can facilitate the prediction of adverse outcomes of COVID-19.en_AU
dc.language.isoenen_AU
dc.subjectCOVID-19en_AU
dc.subjectCoronavirusen_AU
dc.titleMachine learning based on clinical characteristics and chest CT quantitative measurements for prediction of adverse clinical outcomes in hospitalized patients with COVID-19en_AU
dc.typeArticleen_AU
dc.identifier.doi10.1007/s00330-021-07957-z
dc.relation.otherNational Natural Science Foundation of Chinaen_AU


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.